Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System (NCT03067051)
Open-label Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System (Interstitial Multiple Diode Lasers and IDOSE® Software) and Verteporfin for Injection (VFI) for the Treatment of Recurrent Prostate Cancer
🩺 Plain-English Summary (8th-Grade Level)
The rationale for the study is to obtain safety and efficacy data as well as to establish dose parameters for the SpectraCure P18 System with IDOSE®, with verteporfin for injection (VFI) as photosensitizer for the treatment of recurrent prostate cancer.
Who can join: Review the eligibility criteria below.
Location: Memorial Sloan Kettering Cancer Center — New York, New York
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (4 Sites)
- Memorial Sloan Kettering Cancer Center — New York, New York
- Princess Margaret Cancer Centre — Toronto, Ontario
- Skåne University Hospital — Malmö, Skåne County
- Reader in Urology, University College London & Honorary Consultant Urological Surgeon, University College London Hospitals Trust — London,
📞 Contact the Study Coordinator
Phone: +46 (0) 46 16 20 70
Email: jsw@spectracure.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Recurrent Prostate Cancer
- Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer — New York, New York
- Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery — Duarte, California
- Determining Patterns In Trial Experiences of Recurrent Prostate Cancer Patients — San Francisco, California
- IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy — Bethesda, Maryland
- Tumor Microenvironment Analysis of Prostate Cancer Metastasis — New York, New York
Explore by condition: All Recurrent Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.